Navigation Links
VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
Date:11/8/2010

DA. VIVUS received a Complete Response Letter (CRL) from the FDA and is preparing a written response to address the FDA's requests for information included in the CRL. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of male sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction.

For more information about the company, please visit www.vivus.com.  

Note to Investors As previously announced, VIVUS will hold a conference call and an audio webcast to discuss the third quarter financial results today, November 8, 2010, beginning at 1:30 p.m. Pacific Time.  You can listen to this call by dialing 1-877-359-2916 and outside the U.S. 1-224-357-2386. A webcast replay will be available for 30 days and can be accessed at http://ir.vivus.com/.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing and substance of VIVUS' written response to the FDA's complete response letter; the FDA's interpretation of the data VIVUS submits relating to the teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and our sleep apnea study (OB-204); that we may be required to conduct additional clinical trials; our history of losses and variabl
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
2. VIVUS Announces Sale of MUSE Assets to Meda
3. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
4. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Announces Promotion of Peter Tam to President
7. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
8. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
9. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
10. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
11. GenVec Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "12th Annual Report ... report to their offering. The ... Manufacturing Capacity and Production is the most recent ... current and projected future capacity and production. The ...
(Date:8/28/2015)... 2015 Research and ... the "Investigation Report on China,s Insulin Aspart ... Developed by Novo Nordisk, insulin aspart (under ... drug for the treatment of diabetes. Compared with ... insulin analog, starts working fast and reports higher ...
(Date:8/28/2015)... 28, 2015 Perrigo Company plc ("Perrigo") (NYSE: ... N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote regarding ... "Our views of Mylan,s offer to Perrigo shareholders have ... our Board,s careful reflection of the value available to ... choices that Mylan has allowed its shareholders to consider," ...
Breaking Medicine Technology:12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... SYDNEY, Australia, Aug. 17 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... Phase 3,clinical trial of Bronchitol for the treatment ... efficacy data from the trial is expected to ... trial commenced its dosing phase in,April 2007, reached ...
... Activity, VOORHEES, N.J., Aug. 14 ... and mortality in recipients of hematopoietic,stem cell ... are,serious and range from gastrointestinal disease to ... order to prevent CMV infection and reduce ...
Cached Medicine Technology:Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance 2
(Date:8/30/2015)... ... , ... Certified Nutrition Businessman Reid Eckert agrees to extend his business relationship ... global sales and communications firm that offers U.S. brands a proven path to world ... Mr. Reid Eckert, as his interpretation of the nutritional needs of the human body ...
(Date:8/29/2015)... ... August 30, 2015 , ... On September 30, 2015, the Career ... the 10 regionally accredited Maricopa Community Colleges , will be hosting a Job ... pursuing employment information and opportunities. , The Expo has expanded to much more than ...
(Date:8/29/2015)... NC (PRWEB) , ... August 29, 2015 , ... ... how mesothelioma develops, may extend and improve the lives of patients, according to ... website. Click here to read the full article. , The authors ...
(Date:8/29/2015)... ... 29, 2015 , ... People who have heart or lung ... asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with ... problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... management, Decatur County Memorial Hospital recently transitioned management companies to partner with Wound ... Management for their outpatient wound center. , Transitioning wound care management providers ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... to Help Combat Vets, PHILADELPHIA, Feb. 27 ... an expansion by the Department of,Veterans Affairs (VA) of ... to returning combat veterans, is well,ahead of schedule., ... new centers during the,next two years. Fifteen of those ...
... Feb. 27 Although,physician-scientists and supplement manufacturers are ... over multivitamins. In fact, half the,physicians on the ... a,multivitamin themselves. In recent years, Harvard Men,s Health ... even if they don,t,help, they won,t hurt. However, ...
... Fox Chase Cancer Center today announced the first ... to bring the power of team-based science to bear ... research. The Keystone Programs for Collaborative Discovery aim to ... the heart of each of the four new Keystone ...
... new strain,of flu affecting workers nationwide, employers may need ... at the height of flu season,according to CCH, a ... services and a part of Wolters Kluwer Law & ... about half of employers (54 percent) send,workers back home ...
... Children up to 18 years of age would be ... News) -- U.S. health advisers recommended Wednesday that all ... annual flu shots. , Currently, the recommendation is that ... vaccinated. , The recommendation by the U.S. Centers ...
... concerns about potential,skin damage are fuelling an increase ... women who still want a sun-kissed look. But,across ... shelves as Chinese,and Japanese consumers seek the "must ... ), Both trends represent significant growth opportunities ...
Cached Medicine News:Health News:VA Has Added 20 New Vet Centers 2Health News:It's Time to Reassess the Value, Safety of Multivitamin Use, Says Harvard Men's Health Watch 2Health News:Keystone Programs for Collaborative Discovery Launch at Fox Chase 2Health News:Keystone Programs for Collaborative Discovery Launch at Fox Chase 3Health News:CCH Outlines 10 Steps to Keeping the Workplace Healthy in the Height of Flu Season 2Health News:CCH Outlines 10 Steps to Keeping the Workplace Healthy in the Height of Flu Season 3Health News:CCH Outlines 10 Steps to Keeping the Workplace Healthy in the Height of Flu Season 4Health News:CDC Panel Urges Extending Flu Vaccine Coverage for Kids 2Health News:CDC Panel Urges Extending Flu Vaccine Coverage for Kids 3Health News:Health and Fashion - Dow Corning Predicts the Top Trends Driving Consumers to the Beauty Counters 2
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
... technology is the first and ... patented digital sensor all ... sensor. Dolphin ONE™ sensors both ... in the sensor, resulting in ...
... Oil is a clear, colorless oil ... of the UV-VIS spectrum. Resolve is ... viscosity, is non-drying and non-hardening, and ... Resolve contains no PCBs, eliminating toxicity ...
Medicine Products: